- Home
- BLFS vs ADPT Comparison
BLFS vs ADPT Comparison
Compare BLFS & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BLFS | ADPT |
|---|---|---|
| Founded | 1987 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 2.6B |
| IPO Year | 1989 | 2019 |
Fundamental Metrics
Financial Performance| Metric | BLFS | ADPT |
|---|---|---|
| Price | $24.38 | $15.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | ★ $31.50 | $16.60 |
| AVG Volume (30 Days) | 336.2K | ★ 3.0M |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $100,144,000.00 | ★ $252,754,000.00 |
| Revenue This Year | $20.67 | $50.81 |
| Revenue Next Year | $14.13 | $1.17 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 87.53 | 42.57 |
| 52 Week Low | $19.10 | $5.81 |
| 52 Week High | $29.62 | $20.76 |
Technical Indicators
Market Signals| Indicator | BLFS | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 39.63 | 44.33 |
| Support Level | $24.44 | $14.58 |
| Resistance Level | $25.96 | $16.26 |
| Average True Range (ATR) | 0.87 | 1.13 |
| MACD | -0.08 | -0.36 |
| Stochastic Oscillator | 4.36 | 13.75 |
Price Performance
Historical ComparisonAbout BLFS BioLife Solutions Inc.
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).